The present invention relates to a herbal formulation for preventing and treating the metabolic
syndrome when adiponectin is an activator property. The formulation of the present invention
may be advantageous when used for the prevention and treatment of insulin resistance,
dyslipidemia including atherosclerosis and vascular inflammation in patients with metabolic
syndrome particularly beneficial effect On adiponectin, leptin, resistin, serum insulin, glycated
hemoglobin, LDL, triglycerides, interleukin-6, TNF-a, including hs CRP.
Metabolic syndrome is a combined phenomenon of atherogenic dyslipidemia, insulin resistance,
hypertension and obesity. Obesity and the metabolic syndrome have been shown to have a
significant influence on the onset of cardiovascular disorders, particularly in the presence of type
2 diabetes mellitus. The increase in the incidence of obesity has increased significantly The
prevalence of the metabolic syndrome throughout the world. The pro-inflammatory and prothrombotic
state, responsible for endothelial dysfunction is a common feature among cases of
metabolic syndrome. The metabolic syndrome in the state of glucose tolerance, insulin
resistance, dyslipidemia and arterial hypertension presents a prothrombotic state.
It is reported that nearly a quarter of adults and about nine percent of adolescents have metabolic
syndrome. People with metabolic syndrome are twice as likely to develop heart disease and five
times more likely to develop diabetes. The pathogenesis of the metabolic syndrome is genetic
and environmental. Excess abdominal fat, lack of action of insulin and storage of energy are the
main risk factors that play the role in the onset of metabolic syndrome. According to the
Cholesterol Guidelines Education Panel National Adult Treatment Program III (ATP III) for the
identification of metabolic syndrome, the diagnosis relies on the participation of three or more
components together as abdominal obesity, triglycerides, HDL-C, Blood pressure, and fasting
blood glucose levels.
Obesity plays an important role in the development of the metabolic syndrome. Obesity is the
result of an imbalance between energy intake and energy expenditure. Genetic and
environmental factors are the predisposing factor for the weight of the grain and cause obesity.
Obesity requires drastic management due to the pharmacotherapy of unsatisfactory results of diet
control and exercise. Recently, an anti-obesity agent sibutramine appetite suppressant and fat
absorption inhibitor Orlistat, is used for the treatment of metabolic syndrome.
Maximum attention has focused on the identification and treatment of dyslipidemia associated
with the metabolic syndrome. The abnormality in the metabolism of lipids to the accumulation of
abdominal fat is well defined. An increase in the number of small dense particles of LDL is a
constant characteristic of abdominal adiposity dyslipidemia because they are associated with
insulin resistance, intra-abdominal fat and hypertension. LDL comprises a particle spectrum
including size, density, chemical composition and atherogenic potential. The presence of small
dense particles of LDL reduced cholesterol is associated with an increased risk of myocardial
infarction and even worse because of the severity of cardiovascular disease. Due to the
mechanism, small and dense LDL in the arterial wall more readily bind to proteoglycans of the
arterial wall with increased avidity and are susceptible to oxidative modification, leading to
Apolipo-B assessment in the metabolic syndrome can help guide patients for aggressive lipidlowering
treatment. High levels of LDL-c are generally accepted as one of the strongest risk
factors for cardiovascular disease. Insulin resistance is associated with an increase in the number
of small particles of VLDL-C and LDL-c, reflected by higher levels of apolipo-B, with decreased
apolipo-B triglycerides compared to individuals Sensitive insulin. Studies have shown that the
increase in lipoproteins containing apolipo-B and B-apolipo (VLDL and LDL-c-c) are associated
with an increased risk of cardiovascular disease is significantly higher in individuals with
metabolic syndrome.
Evidence suggests an association between chronic inflammation, insulin resistance, obesity, type
2 diabetes mellitus and arteriosclerosis. Recently, workers have reported that chronic
inflammation can increase insulin resistance, and altered beta cell function which are risk factors
for the onset of diabetes.
Many studies have shown that obesity and insulin resistance are associated with higher levels of
inflammatory markers and endothelial function. Thus, the relationship between the different
markers of inflammation in particular of c-reactive proteins and interleukin-6 and the risk of
developing type 2 diabetes is well established. Adiponectin, the adipocyte-derived hormone, has
a potential to negatively regulate inflammatory responses and also to improve glucose tolerance
and insulin resistance. Adiponectin is related to insulin resistance and adiposity in humans and
protects against the risk of developing diabetes.
Recently, adiponectin has been discovered as a potential agent derived from adipose tissue. Low
plasma adiponectin levels are associated with insulin resistance, obesity, atherosclerosis,
dyslipidemia and ultimately leads to heart disease. These hormones have proven to be a key
regulator of insulin sensitivity in humans. Adiponectin is a glycoprotein derived from adipose
tissue that is fully secreted by adipose tissue. Circulating Adiponectin activates the receptor
activated by peroxisome proliferators (PPAR-a) which are responsible for the regulation of
glucose metabolism. Several workers have observed that adiponectenemia hypo is the result of
induced obesity, insulin resistance in adipose tissue. The molecular mechanism of insulin
resistance, especially in adipose tissue, can not be understood in the study of the regulation of the
endocrine system of energy metabolism and the role of various adipokines such as leptin,
ghrelin, Adiponectin and resistin. All these front adipokines are produced by adipose tissue. The
biological effects of adiponectin in humans have been of interest to the pharmacologist who are
looking for sub-specific that can regulate abnormal anergic metabolism and may prevent the
onset of insulin resistance targets 9 Obesity and other complications of the metabolic syndrome.
If insulin resistance, plasma adiponectin is significantly lower, which is also associated with high
levels of the glycemic index of lipoproteins and dyslipidemia. It is reported that variants of the
adiponectin gene have been one of the causes of obesity and insulin resistance.
Given the above facts, undertook to develop a new herbal formulation that have properties to
improve adiponectin in patients with metabolic syndrome so that it can prevent the process of
atheroma and resistance to 1 Insulin and prevent future onset of adverse cardiac events.
Scientific evaluation of some of the Ayurvedic medicines has demonstrated better efficacy
compared to standard drug treatments with or without minimal side effects. Successful
management of the rare metabolic syndrome is once possible with a single entity drug because it
is a disease that brings together a group of abnormalities. In the system of Ayurvedic medicine a
comprehensive description, as well as prevention and management strategies are given for
obesity and diabetes. Thus, taking the lead in the Ayurvedic classics, he prepared the current
formulation tests and evaluation of the scientific parameters involved is validated with the
metabolic syndrome, especially the property of improving adiponectin drug.
OBJECTS OF THE INVENTION
The main object of the present invention is to provide a plant-based formulation having a
property enhancing agent for patients with metabolic syndrome adiponectin can be successfully
treated without any adverse effects.
Another object of the present invention is to provide a plant-based plant formulation which can
improve insulin resistance in patients with metabolic syndrome.
Another object of the present invention is to provide an ayurvedic herbal formulation to be
beneficial in the prevention and management of LDL-C and abnormal lipid triglycerides,
particularly oxidized in patients with metabolic syndrome.
Further, the object of the present invention is to provide an ayurvedic herbal formulation which
has a potential role in the reduction of elevated leptin and adipokines involved in resistance to
the metabolic syndrome.
Yet another object of the present invention is to provide a plant-based formulation of the plant
showing the potential improvement of adiponectin, so that it can be effective in the treatment of
TNF-a-reducing vascular inflammation, IL-6 and hs CRP in patients with metabolic syndrome.
The foregoing has described some of the relevant objects of the invention. These objects are not
to be construed as merely illustrating some of the most important features and applications of the
present invention. Many others can achieve beneficial results applying the invention described in
a different manner or modification of the invention within the scope of the invention.
Accordingly, other objects and a full understanding of the invention and the detailed description
of the preferred embodiment in addition to the scope of the invention are to be defined by the
appended claims.
These and other objects and advantages of the invention will appear from the following
description.
State of the Invention
According to the present invention, a preparation facility for the prevention and management of
the metabolic syndrome for potentiating adiponectin property comprising an effective amount of
extract is provided by hydro-methanolic Salacia reticulata, Tribulus terrestris, Curcuma longa
and hoffe and optionally additives in Quantities.
In other embodiments, the invention is a Dioscorea bulbifera plant formulation comprising at
least two Salacia reticulata extracts and hydro methanol selected from Tribulus terrestris and
Curcuma longa. Exemplary formulations include hydro-methanolic extract Salacia reticulata
from Tribulus terrestris and hoffe; Hydro-methanolic extracts Curcuma longa, hoffe Tribulus
terrestris; Hydro-methanolic extracts Curcuma longa, Salacia reticulata and hoffe; Hydromethanolic
extracts Curcuma longa, hoffe Tribulus terrestris; And hydro-methanolic extracts of
Curcuma longa, Tribulus terrestris, Salacia reticulata and hoffe.
DETAILED DESCRIPTION OF THE INVENTION
It is to be understood at the beginning of the following description that the following description
illustrates only one particular form of the invention. However, this particular form is only an
exemplary embodiment and the teachings of the invention are not intended to be restrictive.
In order to promote a better understanding of the principles of the invention, reference will now
be made to the embodiments and a specific language will be used to describe the same. However
it should be understood that no limitation on the scope of the invention, such alterations and
other modifications in the illustrative and other applications of the principles of the invention as
illustrated contemplated therein as would normally occur The bag are not intended for the man tc
which the invention relates.
The hydro-methanolic extract of Salacia reticulates four ayurvedic plants, Curcuma longa,
Tribulus terrestris hoffe and is prepared using a 50:50 ratio of water and methanol for the
development of this novel formulation. In order to establish the beneficial role of a test
formulation based on experimental and clinical studies were performed mechanism. The water
used for extraction has been decontaminated for any type of bacterial or abnormal growth using z
reverse osmosis plant. After extraction, the active molecules were identified and separated by
HPLC, NMR and HPTLC procedures.
The biological property was determined based on the mode of action of one selected for the
preparation of the formulation plant and the combined formulation by validating its role in the
effects of adiponectin improvement and in particular The improvement of other abnormalities
such as insulin resistance, triglycerides -c, the atherosclerotic process, an inflammatory process
and also reduce leptin and adipocyte resistin in patients with metabolic syndrome.
Prior to use of the drug for human consumption, the preclinical safety profile and efficacy of the
single and combined formulation was performed in accordance with international standards. The
test of anti-obesity anti-atherosclerotic blood glucose lowering activity and evaluated in
experimental models. The animal model of obesity induced by a high-fat diet designed, induced
by a high cholesterol diet high cholesterol and hyperglycemia of diabetes induced by
streptozotocin and the beneficial role of the test formulation on adiponectin, leptin a Was
evaluated, resistin, 6, TNF-a and hs CRP in the experimental models above. A study based on a
mechanism indicated the therapeutic potential of the test drug in the prevention and treatment of
the metabolic syndrome by its adiponectin stimulating activity.

5. CLAIMS (Not applicable for provisional specification. Claims should start with the preamble
- "I/We claim" on separate page)
Having thus described the invention,
1. The combined extracts thus obtained all contain sensitive to the temperature present in the
grass / herbs minor ingredients which may contribute to the therapeutic interest of herbs /
herbs.
2. The extracts do not contain any harmful solvent, carcinogenic or toxic residues.
3. The extracts are more " wholistic" or "total" in terms of beneficial ingredients.
4. Preservation of heat-sensitive elements in extracts, in order to improve (s) grass (s) of
powder.
5. The elimination of harmful solvents extracts beneficial from the pharmacological point of
view.
6. Elimination of the "no" beneficial supports of the formulations.
7. Potential-based herbal powders without any genetic modification, totally ecofriendly in
order to potentiate herbs.
8. Silica used to Air Combine Ingredients also offers health benefits by making all the
formulation ingredients are "beneficial" for healthcare applications.